POTASSIUM CHLORIDE 40MEQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ (POTASSIUM CHLORIDE 40MEQ).
Potassium is the major intracellular cation. It is essential for the maintenance of intracellular tonicity, transmission of nerve impulses, contraction of cardiac, skeletal, and smooth muscle, and maintenance of normal renal function. Replacement therapy corrects hypokalemia.
| Metabolism | Not metabolized; primarily excreted unchanged by the kidneys with minor fecal elimination. |
| Excretion | Renal: >90% of potassium is excreted by the kidneys. Approximately 80-90% of an oral dose is eliminated in urine, with the remainder in feces via intestinal secretion. |
| Half-life | Potassium has no defined elimination half-life as it is a major intracellular ion tightly regulated by homeostatic mechanisms; serum levels reflect distribution and renal function. In anephric patients, the effective half-life is extended significantly. |
| Protein binding | Potassium is minimally protein-bound (<5%), with no specific binding proteins. |
| Volume of Distribution | Approximately 0.5-0.7 L/kg for total body potassium; distributes primarily into intracellular fluid, with only about 2% in extracellular fluid. Clinical meaning: Vd is large due to extensive cellular uptake. |
| Bioavailability | Oral: Approximately 90% for immediate-release formulations; sustained-release formulations have slightly lower bioavailability due to incomplete release. IV: 100%. |
| Onset of Action | Oral: 30-60 minutes for serum potassium elevation; IV: immediate (within minutes) when given as an infusion. |
| Duration of Action | Oral: 4-6 hours for sustained-release formulations; IV: Duration depends on infusion rate and renal function, typically 1-3 hours after stopping infusion. |
40 mEq orally once daily or divided every 6-12 hours; IV infusion at a rate not exceeding 10 mEq/hour with a maximum concentration of 40 mEq/L via peripheral line.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 10-50 mL/min: administer 50% of standard dose; GFR <10 mL/min: avoid potassium chloride or use with extreme caution, close monitoring required. |
| Liver impairment | No specific adjustment per Child-Pugh class; use with caution due to potential electrolyte imbalances, especially in cirrhosis. |
| Pediatric use | 0.5-1 mEq/kg/dose orally or IV, maximum 40 mEq/dose; IV rate not exceeding 0.5-1 mEq/kg/hour. |
| Geriatric use | Start at lower end of dosing range (e.g., 20 mEq/day) due to age-related decline in renal function; monitor serum potassium closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for POTASSIUM CHLORIDE 40MEQ (POTASSIUM CHLORIDE 40MEQ).
| Breastfeeding | Potassium chloride is excreted into breast milk but amounts are not clinically significant. The M/P ratio is approximately 0.5-1.0, reflecting passive diffusion. No adverse effects on nursing infants reported with normal maternal supplementation. |
| Teratogenic Risk | First trimester: No evidence of teratogenicity in human studies; potassium chloride is a physiologic ion not associated with structural anomalies. Second trimester: No known fetal risks; maintains maternal-fetal electrolyte balance. Third trimester: Use is safe; intravenous administration may be necessary for maternal hypokalemia; adverse fetal effects only if maternal toxicity occurs (e.g., hyperkalemia). |
■ FDA Black Box Warning
Potassium chloride injection concentrate must be diluted before use. Undiluted administration can cause cardiac arrest, fatal arrhythmias, or sudden death.
| Serious Effects |
["Hyperkalemia","Severe renal impairment with oliguria or anuria","Addison's disease","Acute dehydration","Adynamic ileus","Concomitant use with potassium-sparing diuretics"]
| Precautions | ["Cardiac arrest and fatal arrhythmias if given undiluted or too rapidly","Hyperkalemia risk in patients with renal impairment","GI ulceration with oral formulations","Monitor serum potassium levels regularly"] |
Loading safety data…
| Fetal Monitoring | Monitor serum potassium levels, renal function, ECG (if hyperkalemia risk), and fluid balance. In pregnancy, assess maternal blood pressure and fetal heart rate during intravenous infusion to avoid volume overload. |
| Fertility Effects | No known effect on human fertility. Animal studies do not indicate reproductive toxicity at therapeutic doses. |